Table 4.
Univariate Analysis of Bleeding of Any Degree in Patients Taking Dabigatran
| Baseline Characteristics | Frequency | P Value |
|---|---|---|
| Sex | ||
| Male | 17/68 (25.0%) | 0.550 |
| Female | 11/54 (20.4%) | |
| Age | ||
| ≥70a | 22/71 (31.0%) | 0.013b |
| <70 | 6/51 (11.8%) | |
| Hypertension | ||
| Yes | 21/85 (24.7%) | 0.489 |
| No | 7/37 (18.9%) | |
| DM | ||
| Yes | 4/35 (11.4%) | 0.056 |
| No | 24/87 (27.6%) | |
| Prior TIA or stroke | ||
| Yes | 13/53 (24.5%) | 0.719 |
| No | 15/69 (21.7%) | |
| Prior GI Bleeding | ||
| Yes | 4/10 (40.0%) | 0.184 |
| No | 24/112 (21.4%) | |
| CKD | ||
| Yes | 5/9 (55.6%) | 0.015b |
| No | 23/113 (20.4%) | |
| Baseline medications | ||
| Aspirin | ||
| Yes | 5/21 (23.8%) | 0.919 |
| No | 23/101 (22.8%) | |
| NSAID | ||
| Yes | 1/2 (50.0%) | 0.363 |
| No | 27/120 (22.5%) |
Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; GI, gastrointestinal; NSAID, nonsteroidal anti‐inflammatory drug; TIA, transient ischemic attack.
a
Age threshold of 70 years old was calculated to have the most statistically significant difference in the rate of bleeding among all age thresholds.
b
denoted P ≤ 0.05.